It is generally observed that triple negative breast cancer patients do not get benefited from endocrine targeted therapies. However, by a thorough Systematic review and critical analysis of the literature it could be depicted that a subset with Androgen Receptor expression could respond to anti-androgen therapies up to some extent. Presented here is a 65-years-old Postmenopausal female with a 5-year history of Carcinoma Right Breast (post-operative Chemotherapy and Radiotherapy) with bone and lung metastases, advanced, Grade III tumor diagnosed as Metastatic Adenocarcinoma on histology. This case had been presented to identify the role of Androgen Receptors in inhibiting and suppressing the tumor growth in breast oncology and to conclude that traditional Anti-Androgen therapy, that is, Bicalutamide could be considered as a differential diagnosis of Triple negative breast cancer metastatic tumors. Therefore, the present article represents some deeper insights regarding Androgen, Androgen-Receptor, Anti-Androgen drug-Bicalutamide and their role of action in the post-menopausal Triple Negative Breast cancer women with positive expression of Androgen Receptor.
Keywords: Breast, Lungs, Carcinoma, Metastasis, Bicalutamide, Androgen Receptor, Post-menopausal, Androgen, Estrogen, HER2, TNBC.
ClinicalTrials.gov [Internet]. Xichun, Hu.: Fudan University (China). 2015 January 18- Identifier NCT02348281, Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients; Accessed on: 2016 March 19; Available from:
ClinicalTrials.gov [Internet]. Schroder, C.P.: University Medical Center Groningen (The Netherlands). 2015 August 25- Identifier NCT02697032, FDHT PET and Bicalutamide in Metastatic Breast Cancer; Accessed on: 2016 March 19; Available from:
ClinicalTrials.gov [Internet]. Guan, X. : Jinling Hospital (China). 2015 January 26- Identifier NCT02353988, AR-inhibitor Bicalutamide in Treating Patients With TNBC (Arbre); Accessed on: 2016 March 19; Available from:
ClinicalTrials.gov [Internet]. Memorial Sloan Kettering Cancer Center (United States). 2007 May 2- Identifier NCT00468715, Bicalutamide in Treating Patients With Metastatic Breast Cancer; Accessed on: 2016 March 19; Available from:
ClinicalTrials.gov [Internet]. Memorial Sloan Kettering Cancer Center (United States). 2015 November 12- Identifier NCT02605486, Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC); Accessed on: 2016 March 19; Available from:
Cochrane, D.R., Bernales, S., Jacobsen, B.M., Cittelly, D.M., Howe, E.N., D’Amato, N.C., Spoelstra, N.S., Edgerton, S.M., Jean, A., Guerrero, J., Gómez, F., Medicherla, S., Alfaro, I.E., McCullagh, E., Jedlicka, P., Torkko, K.C., Thor, A.D., Elias, A.D., Protter, A.A., and Riche, J.K. (2014). Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research, 16, R7. http://doi:10.1186/bcr3599.
Doane, A.S., Danso, M, Lal, P., Donaton, M., Zhang L., Hudis, C., and Gerald, W.L. (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene, 25, 3994–4008. http://doi:10.1038/sj.onc.1209415.
Garay, J. P., & Park, B. H. (2012). Androgen receptor as a targeted therapy for breast cancer. American Journal of Cancer Research, 2(4), 434–445. Available at:
Gucalp, A., Tolaney, S., Isakoff, S.J., Ingle, J.N., Liu, M.C., Carey, L.A., Blackwell, K.., Rugo, H., Nabell, L., Forero, A., Stearns, V., Doane, A.S., Danso, M., Moynahan, M.E., Momen, L.F., Gonzalez, J.M., Akhtar, A., Giri, D.D., Patil, S., Feigin, K.N., Hudis, C.A., and Traina, T.A. (2013). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res, 19, 5505–12. http://doi:10.1158/1078-0432.CCR-12-3327.
Kotsopoulos, J., Narod, S.A. (2012). Androgens and breast cancer. Steroids, 77, 1-9. http://:10.1016/j.steroids.2011.10.002.
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation, 121(7), 2750–2767. http://doi.org/10.1172/JCI45014.
Luo, X., Shi, Y.X., Li, Z.M., Jiang, W.Q. (2010). Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer, 29(6), 585-90. Available at: www.cjcsysu.cn.
Min Ni, M., Yiwen Chen, Y., Elgene Lim, E., Hallie Wimberly, H., Shannon, T., Bailey, S.T., Yuuki Imai, Y., David, L., Rimm, D.L., X. Shirley Liu, X.S., Myles Brown, M. (2011). Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. Cancer Cell, 20, 119-131. http://dx.doi.org/10.1016/j.ccr.2011.05.026.
Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H., Robertson, J.F., Ellis, I.O. (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109(1):25-32. http://doi:10.1002/cncr.22381.
Shibahara, Y., Miki, Y., Sakurada, C., Uchida, K.., Hata, S., McNamara, K.., Yoda, T., Takagi, K.., Nakamura, Y., Suzuki, T., Ishida, T., Ohuchi, N., Sasano, H. (2013). Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Human Pathology, 44, 2338–2345. http://dx.doi.org/10.1016/j.humpath.2013.04.021.
Shipley, W.U., Hunt, D., Lukka, H.R., Major, P., Heney, N.M., Grignon, D., Patel, M., Bahary, J., Lawton, C.A., and Sandler, H.M. (2011). Journal of Clinical Oncology, 29 (7), 1. Available at: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/29/7_suppl/1.
Srikanth, M.V., Janaki Ram, B., Senthil Rajan, D.S., Adinarayana, G. and Ramana Murthy, K.V. (2013). Dissolution rate enhancement of bicalutamide by adsorption process. African Journal of Pharmacy and Pharmacology, 7 (21), 1357-1362. http://doi10.5897/AJPP10.073.
U.S. National Library of Medicine. (Updated 2016, February 24). Bicalutamide. Retrieved March 19, 2016, from Medline Plus: